MedImmune Ventures backs Inotek's $18m fourth round of funding.

A day after hiring corporate venturing veteran Ron Laufer, MedImmune Ventures has joined the fourth round of funding for US-based drug development company Inotek Pharmaceuticals.

Inotek raised $18m in its series D round, with MedImmune, the biotech corporate venturing division of Anglo-Swedish pharmaceuticals company AstraZeneca, reinvesting.

Devon Park Bioventures, a US-based venture capital firm, led the round as a new investor. Other investors were VCs Rho Ventures, Care Capital and Pitango Venture Capital and Bio*One Capital, a part of…

Subscribe to go deeper

GCV subscribers get access to all our proprietary data and deep-dive articles, as well as the global directory of CVC investors.



Not sure if you have a subscription?